Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 961 of 6351
-
New pill combo aims to fight spread of colorectal cancer
Disease control OngoingThis is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer. The patients will be randomized into two arms consist of Anlotinib (3 weeks/cycle) + CapeOx and Bevacizumab (3 week/cycle) + CapeOx at a ratio of…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New strategy aims to boost surgery success in pancreatic cancer
Disease control OngoingThis phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is effective in treating patients with pancreatic cancer th…
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Tiny particles, big hope: new combo tackles tough cancers
Disease control Recruiting nowThis research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and …
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a new drug rescue the liver when standard therapy fails?
Disease control CompletedThe purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase at g…
Phase 2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Glue embolization may cut repeat brain bleed surgery
Disease control CompletedThis is a prospective, multi-center, open-label, randomized controlled study in which subjects can receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization for the treatment of chronic subdural hematomas (cSDH).
Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for kids with IBD: Long-Term drug trial launches
Disease control Recruiting nowThe main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to partic…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could a ketogenic diet boost brain cancer treatment?
Disease control CompletedGlioblastoma (GBM), a very aggressive brain tumour, is one of the most malignant of all cancers and is associated with a poor prognosis. The majority of GBM cells display damaged mitochondria (the "batteries" of cells), so they rely on an alternate method for producing energy cal…
Sponsor: Waikato Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New heart valve fix without Open-Heart surgery shows promise
Disease control CompletedThe Renato® transcatheter valve-in-valve system, developed by Balance Medical, is undergoing a multicenter registry trial across China. The study enrolls patients whose previously implanted surgical or transcatheter bioprosthetic valves have deteriorated and who are at high risk …
Sponsor: Beijing Balance Medical Technology Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:39 UTC
-
New combo therapy offers hope for advanced lung cancer patients
Disease control Recruiting nowIn clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non…
Phase 2 • Sponsor: Zibo Municipal Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingIn this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include …
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail shows promise for tough pancreatic cancer
Disease control CompletedThe main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase 2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo shows promise for rare, aggressive prostate cancer
Disease control OngoingEligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may b…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Nasal spray could ease stage fright for social anxiety sufferers
Symptom relief CompletedThis Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during an induced public speaking challenge. Subject part…
Phase 3 • Sponsor: VistaGen Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 16:19 UTC
-
New hope for tough AML: drug cocktail targets resistant leukemia
Disease control Recruiting nowThis phase Ib/II trials studies the side effects of decitabine/cedazuridine (ASTX727) and venetoclax in combination with ivosidenib or enasidenib, and how well they work in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatmen…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New cocktail aims to tame rare brain cancer
Disease control OngoingThis phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lympho…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Lung cancer drug combo trial halted midway
Disease control Stopped earlyThe purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (…
Phase 3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Double antibiotic attack could beat typhoid resistance
Disease control CompletedTyphoid and paratyphoid (enteric) fever affects more than 11 million children and adults globally each year including 7 million in South Asia. Up to 1% of patients who get typhoid may die of the disease and, in those that survive, a prolonged period of ill health and catastrophic…
Phase 4 • Sponsor: Oxford University Clinical Research Unit, Vietnam • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Sound waves + radiation: new hope for tough brain tumors?
Disease control CompletedThis is an open label, single arm, prospective, and pilot study. Eligible patients will be enrolled after acquiring the signed informed consent and then will receive the treatment of re-RT combined with FUS (FUS + re-RT) on an outpatient basis. The re-RT in FUS + re-RT treatment …
Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail targets rare, aggressive cancer
Disease control Recruiting nowThe purpose is to explore the efficacy and safety of the combination of albumin-bound paclitaxel and liposomal doxorubicin in the treatment of advanced or unresectable angiosarcoma.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Dual-Action drug shows promise in advanced lung cancer trial
Disease control CompletedThis trial is a Phase Ib/II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in subjects with advanced NSCLC wh…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC